BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45-53. [PMID: 27275625 DOI: 10.1111/liv.13186] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 20.7] [Reference Citation Analysis]
Number Citing Articles
1 Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017;9:17-25. [PMID: 28553150 DOI: 10.2147/HMER.S113681] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 13.2] [Reference Citation Analysis]
2 Znaor A, Eser S, Anton-culver H, Fadhil I, Ryzhov A, Silverman BG, Bendahou K, Demetriou A, Nimri O, Yakut C, Bray F. Cancer surveillance in northern Africa, and central and western Asia: challenges and strategies in support of developing cancer registries. The Lancet Oncology 2018;19:e85-92. [DOI: 10.1016/s1470-2045(18)30019-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 4.8] [Reference Citation Analysis]
3 Ghanem SE, Elsabaawy M, Shebl N, Abdelsameea E, Othman W, El-Bassal FI, Elgedawy GA, Elsabaawy DM, Helal ML. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy. Expert Rev Anti Infect Ther 2020;18:947-54. [PMID: 32419526 DOI: 10.1080/14787210.2020.1771180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Montasser IF, Ibrahim AA, Farid HM, Al Balakosy AM. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? Clin Res Hepatol Gastroenterol 2021;45:101517. [PMID: 32900667 DOI: 10.1016/j.clinre.2020.07.022] [Reference Citation Analysis]
5 Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8:1661. [PMID: 29374178 DOI: 10.1038/s41598-017-17936-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
6 Lemoine M, Cooke GS. The Egyptian hepatitis C programme: A model of HCV treatment intervention? J Hepatol 2018;68:638-9. [PMID: 29409777 DOI: 10.1016/j.jhep.2018.01.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 [DOI: 10.1101/2020.03.27.011841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Shousha HI, Saad Y, Saleh DA, Dabes H, Alserafy M, ElShazly Y, Said M. Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2020;32:1017-22. [PMID: 31789947 DOI: 10.1097/MEG.0000000000001612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fadriquela A, Kim CS, Lee KJ, Kang SH, Kim MY, Lee JH. Soluble type immune checkpoint regulators using multiplex luminex immunoassay in chronic hepatitis B patients. J Clin Pathol 2021:jclinpath-2020-207125. [PMID: 34016716 DOI: 10.1136/jclinpath-2020-207125] [Reference Citation Analysis]
10 Attia D, El Saeed K, Elakel W, El Baz T, Omar A, Yosry A, Elsayed MH, Said M, El Raziky M, Anees M. The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients. Aliment Pharmacol Ther. 2018;47:1296-1305. [PMID: 29504152 DOI: 10.1111/apt.14538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
11 Kamal EM, El-Shabrawi M, El-Khayat H, Yakoot M, Sameh Y, Fouad Y, Attia D. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. Liver Int. 2020;40:319-323. [PMID: 31758735 DOI: 10.1111/liv.14308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
12 El-Khayat HR, Kamal EM, El-Sayed MH, El-Shabrawi M, Ayoub H, RizK A, Maher M, El Sheemy RY, Fouad YM, Attia D. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther. 2018;47:838-844. [PMID: 29349793 DOI: 10.1111/apt.14502] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
13 Mahmoud AA, Hassan MH, Ghweil AA, Abdelrahman A, Mohammad AN, Ameen HH. Urinary 8-hydroxydeoxyguanosine in relation to XRCC1 rs25487 G/A (Arg399Gln) and OGG1 rs1052133 C/G (Ser326Cys) DNA repair genes polymorphisms in patients with chronic hepatitis C and related hepatocellular carcinoma. Cancer Manag Res 2019;11:5343-51. [PMID: 31354343 DOI: 10.2147/CMAR.S209112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
14 Fadhil I, Alkhalawi E, Nasr R, Fouad H, Basu P, Camacho R, Alsaadoon H. National cancer control plans across the Eastern Mediterranean region: challenges and opportunities to scale-up. Lancet Oncol 2021;22:e517-29. [PMID: 34735820 DOI: 10.1016/S1470-2045(21)00410-1] [Reference Citation Analysis]
15 El Aggan H, Farahat N, El Deeb N, Zeid A, El-Shendidi A. Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury. Microb Pathog 2019;131:65-74. [PMID: 30926417 DOI: 10.1016/j.micpath.2019.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Njouom R, Siffert I, Texier G, Lachenal G, Tejiokem MC, Pépin J, Fontanet A. The burden of hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective. J Viral Hepat 2018;25:959-68. [PMID: 29533500 DOI: 10.1111/jvh.12894] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Schröeder SE, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Binti Mohamed R, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, Thursz M, Walker T, Hellard M, Howell J. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver Int 2019;39:1818-36. [PMID: 31433902 DOI: 10.1111/liv.14222] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
18 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
19 Abdallah OM, Abdel-megied AM, Gouda AS. Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method. Luminescence 2018;33:1094-100. [DOI: 10.1002/bio.3514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Sliem HA, Salem AS, Hussien WM, El Sayed HRA. Arterial wall structural changes in noncirrhotic chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2019;31:1432-8. [PMID: 31569123 DOI: 10.1097/MEG.0000000000001429] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M, Martin NK, May MT, Averhoff F, Vickerman P. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol 2018;47:550-60. [PMID: 29309592 DOI: 10.1093/ije/dyx270] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
22 Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol Immunol 2021;65:352-72. [PMID: 33990999 DOI: 10.1111/1348-0421.12916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 El-ansary MR, Asaad A, Khalifa R, Abdel Rahman AT, Abd Elsalam AE. Antiviral and immunomodulatory effects of oral bovine lactoferrin therapy among patients with chronic hepatitis C: . Egyptian Liver Journal 2016;6:81-8. [DOI: 10.1097/01.elx.0000522249.08166.ef] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Elbahrawy A, Elwassief A, Abdallah AM, Kasem A, Mostafa S, Makboul K, Ali MS, Alashker A, Eliwa AM, Shahbah H. Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates. J Transl Int Med. 2017;5:164-168. [PMID: 29085789 DOI: 10.1515/jtim-2017-0024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Ghazy AA, Osman EM, Rashwan EA, Gaballah AH, Mostafa H, Tawfik S. Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients. J Med Virol 2019;91:2166-73. [PMID: 31368531 DOI: 10.1002/jmv.25559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Abdelhamid AA, Sherief MH, Nemr NA, Hassoba HM, El-Sakka AI. Homocysteine, insulin-like growth factor one and oestrogen levels in patients with erectile dysfunction-associated chronic hepatitis C virus infection. Andrologia 2018;50:e13116. [PMID: 30063074 DOI: 10.1111/and.13116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Ahmed AMA, Temerk HA, Galal HR, Bazeed SES, Sultan S. The seropervelance of infectious hepatitis viruses (HBV, HCV and HEV) among blood donors and their correlation to risk factors in Qena governorate, Upper Egypt. Virusdisease 2020;31:292-8. [PMID: 32904769 DOI: 10.1007/s13337-020-00589-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Elsadek HM, Abdelbaser ES, Emara MH, Soliman HH, Farag AA. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients. Eur J Gastroenterol Hepatol 2020;32:1046-53. [PMID: 33216478 DOI: 10.1097/MEG.0000000000001695] [Reference Citation Analysis]
29 El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review. J Adv Res 2019;17:43-8. [PMID: 31193326 DOI: 10.1016/j.jare.2019.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K, Kabil K, Hassany M, Shawky A, Yosry A, Shaker MK, ElShazly Y, Waked I, Esmat G, Doss W. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat. 2017;24:262-267. [PMID: 28145032 DOI: 10.1111/jvh.12668] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 17.8] [Reference Citation Analysis]
31 Ahmed M, Mansey AE, Wahsh EA, Gomaa AA, Rabea HM. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection. Curr Med Sci 2021;41:581-6. [PMID: 34047942 DOI: 10.1007/s11596-021-2363-9] [Reference Citation Analysis]
32 Sherief LM, Ragab SM, Helwa MA, Kamal NM, Afify MR, Mohammed RTS, Mokhtar GAE, Sherbiny HS. CMV, B and C hepatitis among multi-transfused hereditary hemolytic Anemia children: an updated Egyptian experience. Ital J Pediatr 2021;47:117. [PMID: 34039385 DOI: 10.1186/s13052-021-01072-x] [Reference Citation Analysis]
33 FitzSimons D, Hendrickx G, Hallauer J, Larson H, Lavanchy D, Lodewyckx I, Shouval D, Ward J, Van Damme P. Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: a roundtable meeting report. Hepatol Med Policy 2016;1:16. [PMID: 30288319 DOI: 10.1186/s41124-016-0022-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
34 Dahab AA, Youssef MM, Eid HM, Elsadi KW. Reporting the Undiagnosed Cases of Hepatitis B and Hepatitis C Viruses among Patients Undergoing Elective Eye Surgery in a Specialized Eye Hospital in Egypt. J Ophthalmol 2019;2019:3985865. [PMID: 31341650 DOI: 10.1155/2019/3985865] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, Jean K, El Tahan A, Sweedy AT, Afify S, Youssef NF. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis. J Viral Hepat. 2018;25:623-630. [PMID: 29274197 DOI: 10.1111/jvh.12854] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
36 Indolfi G, Giannini EG. Hepatitis C virus therapy in children: No one should be left behind. Liver Int 2020;40:283-5. [PMID: 31967401 DOI: 10.1111/liv.14331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Aboushady M, Alwassief A, Abdelrazik M, Ziada D, Shahba H, Elmestikawy A, Elbahrawy A. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. J Interferon Cytokine Res 2019;39:539-46. [PMID: 31173550 DOI: 10.1089/jir.2019.0041] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 [PMID: 33967553 DOI: 10.3748/wjg.v27.i16.1728] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 El Kassas M, Elbaz T, Elsharkawy A, Omar H, Esmat G. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev Anti Infect Ther. 2018;16:345-350. [PMID: 29506418 DOI: 10.1080/14787210.2018.1448709] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
40 Darweesh SK, Yosry A, Salah M, Zayed N, Khairy A, Awad A, Mabrouk M, Albuhairi A. Acoustic radiation forced impulse-based splenic prediction model using data mining for the noninvasive prediction of esophageal varices in hepatitis C virus advanced fibrosis. Eur J Gastroenterol Hepatol 2019;31:1533-9. [PMID: 31689264 DOI: 10.1097/MEG.0000000000001458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
41 Hassany M, Elsharkawy A, Maged A, Mehrez M, Asem N, Gomaa A, Mostafa Z, Abbas B, Soliman M, Esmat G. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol 2018;30:876-81. [PMID: 29727383 DOI: 10.1097/MEG.0000000000001152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
42 Fouad HM, Sabry MA, Ahmed A, Hassany M, Al Soda MF, Abdel Aziz H. Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection. J Pediatric Infect Dis Soc. 2020;9:386-389. [PMID: 31310312 DOI: 10.1093/jpids/piz041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 El-Khayat H, Kamal EM, Yakoot M, Gawad MA, Kamal N, El Shabrawi M, Sameh Y, Haseeb A, Fouad Y, Attia D. Effectiveness of 8-week sofosbuvir/Ledipasvir in the adolescent chronic hepatitis C-infected patients. Eur J Gastroenterol Hepatol. 2019;31:1004-1009. [PMID: 30676473 DOI: 10.1097/meg.0000000000001360] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
44 Youssef SS, Abbas EAER, Youness RA, Elemeery MN, Nasr AS, Seif S. PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression. Arch Physiol Biochem 2019;:1-7. [PMID: 31793339 DOI: 10.1080/13813455.2019.1694039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
45 Ismail SA, Cuadros DF, Benova L. Hepatitis B in Egypt: A cross-sectional analysis of prevalence and risk factors for active infection from a nationwide survey. Liver Int 2017;37:1814-22. [PMID: 28481452 DOI: 10.1111/liv.13469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
46 Musa NI, Mohamed IE, Abohalima AS. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00035-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Acosta S, Salim S. Management of Acute Mesenteric Venous Thrombosis: A Systematic Review of Contemporary Studies. Scand J Surg 2021;110:123-9. [PMID: 33118463 DOI: 10.1177/1457496920969084] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 [DOI: 10.1101/2020.08.20.20176214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Wahab MA, Shehta A, Elshoubary M, Yassen AM, Elmorshedi M, Salah T, Sultan AM, Fathy O, Elsarraf WR, Shiha U, Zalata K, Elghawalby AN, Eldesoky M, Monier A, Said R, Elsabagh AM, Ali M, Kandeel A, Abdalla U, Aboelella M, Elsadany M, Abdel-Khalek EE, Marwan A, ElMorsi FM, Adly R. Living-Donor Liver Transplantation in Hepatitis C Virus Era: A Report of 500 Consecutive Cases in a Single Center. Transplant Proc 2018;50:1396-406. [PMID: 29880362 DOI: 10.1016/j.transproceed.2018.02.085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
50 Nasser MZ, Zayed NA, Mohamed AM, Attia D, Esmat G, Khairy A. Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab J Gastroenterol 2019;20:198-204. [PMID: 31806407 DOI: 10.1016/j.ajg.2019.11.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Abo-Amer YE, Abd-Elsalam S, Eldosoky H, ELShenawy AK, Awny S, Elagawy W, Abgeegy ME, Elsergany HF, Elashry H, Negm MS. Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt. Infect Drug Resist 2018;11:2435-41. [PMID: 30538509 DOI: 10.2147/IDR.S183462] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
52 Ezzeldin E, Abo-Talib NF, Tammam MH, Asiri YA, Amr AEE, Almehizia AA. Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms. Molecules 2020;25:E4611. [PMID: 33050433 DOI: 10.3390/molecules25204611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 El Kassas M, Abdelkader H, Medhat MA. COVID-19 in Egypt: Through crisis to adaptation; a gastroenterologist's perspective. Arab J Gastroenterol. 2020;21:207-210. [PMID: 32798187 DOI: 10.1016/j.ajg.2020.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Traeger MW, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, El-Hayek C, Asselin J, Polkinghorne V, Membrey D, Bramwell F, Carter A, Guy R, Stoové MA, Hellard ME; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS). The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services. PLoS One 2020;15:e0235445. [PMID: 32603349 DOI: 10.1371/journal.pone.0235445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Shousha HI, Abdelaziz AO, Nabeel MM, Omran DA, Abdelmaksoud AH, Elbaz TM, Salah A, Harb STE, Hosny KA, Osman A, Atef M, Gaber A, Zayed NA, Yosry AA, Leithy R. Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade. Pathog Glob Health 2021;:1-9. [PMID: 34494507 DOI: 10.1080/20477724.2021.1975081] [Reference Citation Analysis]
57 Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med 2018;16:175. [PMID: 30296935 DOI: 10.1186/s12916-018-1162-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
58 El Batae H, Amer I, Kobtan A, Saied SM, Ghazy A, Elkalla F, El Sharawy S. Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt. J Med Virol 2018;90:1745-9. [PMID: 29981144 DOI: 10.1002/jmv.25249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Eletreby R, Elakel W, Said M, El Kassas M, Seif S, Elbaz T, El Raziky M, Abdel Rehim S, Zaky S, Fouad R, Gamal Eldeen H, Abdo M, Korany M, Yosry A, El Serafy M, El-Sayed MH, ElShazly Y, Waked I, Doss W, Esmat G. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37:534-541. [PMID: 27712017 DOI: 10.1111/liv.13266] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
60 El-Khazragy N, El Sayed N, Salem AM, Hassan NS, Abdelmoeaz AT, Maher AM, Mansy AE. IL-28β gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients. J Cell Biochem 2018. [PMID: 30450628 DOI: 10.1002/jcb.28096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
61 Ayoub HH, Al Kanaani Z, Abu-Raddad LJ. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. J Viral Hepat 2018;25:670-9. [PMID: 29345847 DOI: 10.1111/jvh.12864] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
62 Toraih EA, Alrefai HG, Hussein MH, Helal GM, Khashana MS, Fawzy MS. Overexpression of heat shock protein HSP90AA1 and translocase of the outer mitochondrial membrane TOM34 in HCV-induced hepatocellular carcinoma: A pilot study. Clin Biochem 2019;63:10-7. [PMID: 30521791 DOI: 10.1016/j.clinbiochem.2018.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
63 Gadallah M, Abdelmoniem W, Fawzy M, Mokhtar A, Mohsen A. Multicenter screening of diabetic patients for detecting new cases of tuberculosis: an approach to intensify the case detection rate of tuberculosis in developing countries with high prevalence of diabetes. J Prev Med Hyg 2019;60:E343-8. [PMID: 31967091 DOI: 10.15167/2421-4248/jpmh2019.60.4.883] [Reference Citation Analysis]
64 Hamdy S, Osman AM, Zakaria ZA, Galal I, Sobhy M, Hashem M, Allam WR, Abdel-samiee M, Rewisha E, Waked I, Abdelwahab SF. Association of Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide polymorphisms with hepatitis C virus persistence among Egyptians. Arch Virol 2018;163:2433-42. [DOI: 10.1007/s00705-018-3893-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
65 Teaima MH, Al-Nuseirat A, Abouhussein D, Badary OA, El-Nabarawi MA. Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study. J Pharm Policy Pract 2021;14:106. [PMID: 34915937 DOI: 10.1186/s40545-021-00389-6] [Reference Citation Analysis]
66 Metwally K, Fouad T, Assem M, Abdelsameea E, Yousery M. Predictors of Spontaneous Bacterial Peritonitis in Patients with Cirrhotic Ascites. J Clin Transl Hepatol 2018;6:372-6. [PMID: 30637213 DOI: 10.14218/JCTH.2018.00001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
67 Hassan AM, Osman HA, Mahmoud HS, Hassan MH, Hashim AA, Ameen HH. Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experience. Infect Drug Resist 2018;11:895-901. [PMID: 29983581 DOI: 10.2147/IDR.S167093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 El-Nahaas SM, Fouad R, Elsharkawy A, Khairy M, Elhossary W, Anwar I, Abdellatif Z, Maher RM, Bekheet N, Esmat G. High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. Eur J Gastroenterol Hepatol 2018;30:1194-9. [PMID: 30096091 DOI: 10.1097/MEG.0000000000001228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
69 El-Ghitany EM, Farghaly AG. Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon 2019;5:e02249. [PMID: 31463388 DOI: 10.1016/j.heliyon.2019.e02249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
70 Ali ME, Halby HM, Ali MY, Hassan EA, El-Mokhtar MA, Sayed IM, Thabet MM, Fouad M, El-Ashmawy AM, Mahran ZG. Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. Viruses 2021;13:2008. [PMID: 34696438 DOI: 10.3390/v13102008] [Reference Citation Analysis]
71 Almaeen AH, Alduraywish AA, Mobasher MA, Almadhi OIM, Nafeh HM, El-Metwally TH. Oxidative stress, immunological and cellular hypoxia biomarkers in hepatitis C treatment-naïve and cirrhotic patients. Arch Med Sci 2021;17:368-75. [PMID: 33747272 DOI: 10.5114/aoms.2019.91451] [Reference Citation Analysis]
72 Emile SH. Predictive Factors for Intestinal Transmural Necrosis in Patients with Acute Mesenteric Ischemia. World J Surg 2018;42:2364-72. [DOI: 10.1007/s00268-018-4503-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
73 Esmat G, Elbaz T, Elsharkawy A, Abdullah M, El Kassas M. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Rev Anti Infect Ther 2020;18:637-42. [PMID: 32302245 DOI: 10.1080/14787210.2020.1758065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Hussein S, Mohamed D, Hafez R. Risk factors of hematological malignancies in Upper Egypt: a case–control study. Egypt J Intern Med 2019;31:171-7. [DOI: 10.4103/ejim.ejim_81_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
75 Shousha HI, Said M, ElAkel W, ElShafei A, Esmat G, Waked E, Elsayed MH, Doss W, Elrazky M, Mehrez M, Hassany M, Zeyada D, Anis M, Alserafy M. Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles. J Infect Public Health 2020;13:1322-9. [PMID: 32473817 DOI: 10.1016/j.jiph.2020.05.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
76 Ahsan A, Khan AZ, Javed H, Mirza S, Chaudhary SU, Shahzad-Ul-Hussan S. Estimation of hepatitis C prevalence in the Punjab province of Pakistan: A retrospective study on general population. PLoS One 2019;14:e0214435. [PMID: 30943224 DOI: 10.1371/journal.pone.0214435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
77 Fouad TR, Abdelsameea E, Abdel‐razek W, Attia A, Mohamed A, Metwally K, Naguib M, Waked I. Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post‐therapeutic outcome and prognostic indicators. Journal of Gastroenterology and Hepatology 2019;34:1604-10. [DOI: 10.1111/jgh.14659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
78 Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45-53. [PMID: 27275625 DOI: 10.1111/liv.13186] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 20.7] [Reference Citation Analysis]
79 Mohamed EI, El-Ghnam SM, Bayoumi AM, Abdel-Mageed SM, Ghareeb DA, Ross B. Electronic nose versus quadrupole mass spectrometry for identifying viral hepatitis C patients. J Viral Hepat 2021. [PMID: 34773341 DOI: 10.1111/jvh.13630] [Reference Citation Analysis]
80 Alem SA, Abdellatif Z, Mabrouk M, Zayed N, Elsharkawy A, Khairy M, Musa S, Anwar I, Yosry A. Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. Abdom Radiol (NY). 2019;44:2751-2758. [PMID: 31028432 DOI: 10.1007/s00261-019-02031-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
81 Aboul Enein AA, Khaled IAA, Khorshied MM, Abdel-Aziz AO, Zahran N, El Saeed AM, Shousha HI, Abdel Rahman HA. Genetic variations in DNA-repair genes (XRCC1, 3, and 7) and the susceptibility to hepatocellular carcinoma in a cohort of Egyptians. J Med Virol 2020. [PMID: 32281666 DOI: 10.1002/jmv.25873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C. The Elimination of Hepatitis C as a Public Health Threat. Cold Spring Harb Perspect Med 2020;10:a036939. [PMID: 31712223 DOI: 10.1101/cshperspect.a036939] [Reference Citation Analysis]
83 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
84 Moustafa H, Madkour M, Hamed F, Abouelnazar S, Abo Elwafa R, Moaaz M. Modulation of Memory B Cell Phenotypes and Toll-Like Receptor-7 in Chronic Hepatitis C Virus Infection During Direct-Acting Antiviral Interferon-Free Therapy: Correlation with Interleukin-7. Viral Immunol 2021;34:227-40. [PMID: 33180667 DOI: 10.1089/vim.2020.0110] [Reference Citation Analysis]
85 El-Mokhtar MA, Elgendy SG, Eldin AS, Hassan EA, Hasan AAA, Abdel Hameed MR, Sayed D, Salama EH. Hepatitis C Virus Affects Tuberculosis-Specific T Cells in HIV-Negative Patients. Viruses 2020;12:E101. [PMID: 31952232 DOI: 10.3390/v12010101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
86 Rashed WM, Kandeil MAM, Mahmoud MO, Ezzat S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst 2020;32:5. [PMID: 32372179 DOI: 10.1186/s43046-020-0016-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
87 Zakaria ZA, Knapp S, Hashem M, Zaghla H, Thursz M, Waked I, Abdelwahab S. Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunol Res 2019;67:123-33. [PMID: 30402710 DOI: 10.1007/s12026-018-9035-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Fares MY, Abdelwahab NS, Abdelrahman MM, Abdel-Rahman HM. Determination of sofosbuvir with two co-administered drugs; paracetamol and DL-methionine by two chromatographic methods. Application to a pharmacokinetic study. Bioanalysis 2019;11:349-64. [PMID: 30873855 DOI: 10.4155/bio-2018-0191] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
89 Shiha G, Soliman R, Mikhail NNH, Easterbrook P. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals. J Hepatol 2021;74:303-11. [PMID: 32931878 DOI: 10.1016/j.jhep.2020.09.008] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Boraie MB, Elnaggar YA, Ahmed MO, Mahmoud AM. Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study). Diabetes Metab Syndr 2019;13:2641-6. [PMID: 31405688 DOI: 10.1016/j.dsx.2019.07.032] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
91 Hassany M, Gamal A, Zaki N, Eysa B. Assessment of the Relation Between SNP in MxA Gene and the Responsiveness of Egyptian HCV Genotype 4 Patients to Pegylated Interferon and Ribavirin Treatment. Gastroenterology Res 2017;10:100-5. [PMID: 28496530 DOI: 10.14740/gr810w] [Reference Citation Analysis]
92 Nomair AM, Issa NM, Madkour MA, Shamseya MM. The clinical significance of serum miRNA-224 expression in hepatocellular carcinoma. Clin Exp Hepatol 2020;6:20-7. [PMID: 32166120 DOI: 10.5114/ceh.2020.93052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
93 Mekky MA, Riad AR, Gaber MA, Abdel-malek MO, Swifee YM. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial. Arab Journal of Gastroenterology 2018;19:76-9. [DOI: 10.1016/j.ajg.2018.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
94 Bettaieb J, Chouikha A, Khedhiri M, Kharroubi G, Badreddine M, Bel Hadj Hmida N, Gharbi A, Hammemi W, Sadraoui A, Ben Yahia A, Meddeb Z, Ben Salah A, Triki H. Hepatitis C virus epidemiology in Central-West Tunisia: a population-based cross-sectional study. Arch Virol 2019;164:2243-53. [PMID: 31179516 DOI: 10.1007/s00705-019-04308-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
95 Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Hepatol Int 2018;12:348-55. [PMID: 29754329 DOI: 10.1007/s12072-018-9868-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
96 Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018; 10(9): 549-557 [PMID: 30310533 DOI: 10.4254/wjh.v10.i9.549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
97 Youssef AA, Magdy N, Hussein LA, El-Kosasy AM. Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt. J Chromatogr Sci 2019;57:636-43. [PMID: 31063182 DOI: 10.1093/chromsci/bmz038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
98 Shahin AA, Zayed HS, Elrefai RM, Taher H, Elsaie A, Senara SH, Fathi HM, Omar G, Abd Elazeem MI. The distribution and outcome of vasculitic syndromes among Egyptians: A multi-centre study including 630 patients. The Egyptian Rheumatologist 2018;40:243-8. [DOI: 10.1016/j.ejr.2018.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
99 Aboubakar M, Kpossou AR, Glago BRGH, Aguiah AG, Mboreha ZH, Sehonou J. [Prevention and factors associated with anti-HCV carriage in pregnant women living in Cotonou]. Pan Afr Med J 2020;36:182. [PMID: 32952826 DOI: 10.11604/pamj.2020.36.182.23122] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Rayan Da'as S, Azzeh M. Subgenotyping and genetic variability of hepatitis C virus in Palestine. PLoS One 2019;14:e0222799. [PMID: 31589628 DOI: 10.1371/journal.pone.0222799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Abdallah OM, Abdel-Megied AM, Gouda AS. Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study. Biomed Chromatogr 2018;32:e4186. [PMID: 29314090 DOI: 10.1002/bmc.4186] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
102 Mosaad YM, Metwally SS, Farag RE, Lotfy ZF, Abdeltwab HE. Association between Toll-Like Receptor 3 ( TLR3 ) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCV. Immunological Investigations 2019;48:321-32. [DOI: 10.1080/08820139.2018.1527851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
103 Saad Y, Awad A, Alakel W, Doss W, Awad T, Mabrouk M. Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients. Eur J Gastroenterol Hepatol 2018;30:201-6. [PMID: 29099423 DOI: 10.1097/MEG.0000000000001008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Hashem M, Jhaveri R, Saleh DA, Sharaf SA, El-Mougy F, Abdelsalam L, Shardell MD, El-Ghazaly H, El-Kamary SS. Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele. Clin Infect Dis 2017;65:999-1005. [PMID: 28903504 DOI: 10.1093/cid/cix445] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
105 Abdelaziz AO, Shousha HI, Said EM, Soliman ZA, Shehata AA, Nabil MM, Abdelmaksoud AH, Elbaz TM, Abdelsalam FM. Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2018;30:1384-8. [PMID: 30179227 DOI: 10.1097/MEG.0000000000001196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Gadallah M, Kandil S, Mohsen A. Association between hepatitis C infection and cerebro-cardiovascular disease: analysis of a national population-based survey in Egypt. Trop Med Int Health 2018;23:738-47. [PMID: 29723920 DOI: 10.1111/tmi.13068] [Reference Citation Analysis]
107 Talaat M, Afifi S, Reaves EJ, Abu Elsood H, El-Gohary A, Refaey S, Hammad R, Abdel Fadeel M, Kandeel A. Evidence of sustained reductions in the relative risk of acute hepatitis B and C virus infections, and the increasing burden of hepatitis a virus infection in Egypt: comparison of sentinel acute viral hepatitis surveillance results, 2001-17. BMC Infect Dis 2019;19:159. [PMID: 30764780 DOI: 10.1186/s12879-019-3806-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
108 Elsharkawy A, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. J Hepatol. 2017;. [PMID: 29223371 DOI: 10.1016/j.jhep.2017.11.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
109 Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Prevalence of hepatitis C virus among street children in Iran. Infect Dis Poverty 2018;7:88. [PMID: 30269685 DOI: 10.1186/s40249-018-0469-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
110 Chin-Yee B, Subramanian SV, Verma AA, Laupacis A, Razak F. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy. Milbank Q 2018;96:369-401. [PMID: 29870114 DOI: 10.1111/1468-0009.12328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
111 Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752 [PMID: 34904042 DOI: 10.4254/wjh.v13.i11.1743] [Reference Citation Analysis]
112 Bayomy Helal HE, Yuonis A, Shaker RHM, Elawady MA. Prevalence of HCV Infection in Household Contacts of Chronic Liver Diseases Cases in Egypt. J Environ Public Health 2018;2018:2153537. [PMID: 30473711 DOI: 10.1155/2018/2153537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Shiha G, Soliman R, Mikhail NNH, Easterbrook P. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages. J Hepatol. 2020;72:658-669. [PMID: 31734097 DOI: 10.1016/j.jhep.2019.11.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
114 Mourad L, El-Ahwany E, Zoheiry M, Abu-Taleb H, Hassan M, Ouf A, Rahim AA, Hassanien M, Zada S. Expression analysis of liver-specific circulating microRNAs in HCV-induced hepatocellular Carcinoma in Egyptian patients. Cancer Biol Ther 2018;19:400-6. [PMID: 29333940 DOI: 10.1080/15384047.2018.1423922] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
115 Anwar WA, El Gaafary M, Girgis SA, Rafik M, Hussein WM, Sos D, Mossad IM, Fontanet A, Temime L. Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt. PLoS One 2021;16:e0246836. [PMID: 33556152 DOI: 10.1371/journal.pone.0246836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]